Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)

impe0096fc17.3 | Diabetes and Insulin 2 | IMPE2023

Pharmacologic inhibition of myostatin with a myostatin antibody protects against muscle and bone loss in an STZ-induced mouse model of type 1 diabetes

Kalaitzoglou Evangelia , Adatorwovor Reuben , Smith Rebecca , Ray Philip , Keeble Alexander , Fry Christopher , Uppuganti Sasidhar , Nyman Jeffry , Fowlkes John , Clay Bunn R.

Type 1 diabetes (T1D) is associated with low bone and muscle mass, increased fracture risk and impaired skeletal muscle function. Myostatin (GDF8), a myokine that is systemically elevated in humans with T1D, negatively regulates muscle mass and bone formation. We investigated whether an inhibitory myostatin antibody in streptozotocin (STZ)-induced diabetes mouse model is protective for bone and skeletal muscle. DBA/2J male mice (n=9 -10/group) were injected with low-d...